A Dual Phosphoinositide-3-kinase Alpha/mTOR Inhibitor Cooperates with Blockade of Epidermal Growth Factor Receptor in PTEN-mutant Glioma

Overview

Journal Cancer Res

Specialty Oncology

Date 2007 Sep 7

PMID 17804702

Citations 99

Authors

Qi-Wen Fan

Christine K Cheng

Theodore P Nicolaides

Christopher S Hackett

Zachary A Knight

Kevan M Shokat

William A Weiss

Affiliations

Soon will be listed here.

Abstract

We have shown previously that blockade of epidermal growth factor receptor (EGFR) cooperates with a pan-selective inhibitor of phosphoinositide-3-kinase (PI3K) in EGFR-driven glioma. In this communication, we tested EGFR-driven glioma differing in PTEN status, treating with the EGFR inhibitor erlotinib and a novel dual inhibitor of PI3Kalpha and mTOR (PI-103). Erlotinib blocked proliferation only in PTEN(wt) cells expressing EGFR. Although erlotinib monotherapy showed little effect in PTEN(mt) glioma, PI-103 greatly augmented the antiproliferative efficacy of erlotinib in this setting. To address the importance of PI3K blockade, we showed in PTEN(mt) glioma that combining PI-103 and erlotinib was superior to either monotherapy or to therapy combining erlotinib with either rapamycin (an inhibitor of mTOR) or PIK-90 (an inhibitor of PI3Kalpha). These experiments show that a dual inhibitor of PI3Kalpha and mTOR augments the activity of EGFR blockade, offering a mechanistic rationale for targeting EGFR, PI3Kalpha, and mTOR in the treatment of EGFR-driven, PTEN-mutant glioma.

Citing Articles

Unveiling the Role of Mechanistic Target of Rapamycin Kinase (MTOR) Signaling in Cancer Progression and the Emergence of MTOR Inhibitors as Therapeutic Strategies.

Mehta D, Rajput K, Jain D, Bajaj A, Dasgupta U ACS Pharmacol Transl Sci. 2024; 7(12):3758-3779.

PMID: 39698262 PMC: 11650738. DOI: 10.1021/acsptsci.4c00530.

Gliomagenesis, Epileptogenesis, and Remodeling of Neural Circuits: Relevance for Novel Treatment Strategies in Low- and High-Grade Gliomas.

Grimi A, Bono B, Lazzarin S, Marcheselli S, Pessina F, Riva M Int J Mol Sci. 2024; 25(16).

PMID: 39201639 PMC: 11354416. DOI: 10.3390/ijms25168953.

Advances in synthetic lethality modalities for glioblastoma multiforme.

Richard S Open Med (Wars). 2024; 19(1):20240981.

PMID: 38868315 PMC: 11167713. DOI: 10.1515/med-2024-0981.

Novel Natural Inhibitors for Glioblastoma by Targeting Epidermal Growth Factor Receptor and Phosphoinositide 3-kinase.

Ullah A, Ullah S, Waqas M, Khan M, Ur Rehman N, Khalid A Curr Med Chem. 2024; 31(40):6596-6613.

PMID: 38616761 DOI: 10.2174/0109298673293279240404080046.

Phosphocatalytic Kinome Activity Profiling of Apoptotic and Ferroptotic Agents in Multiple Myeloma Cells.

Logie E, Perez Novo C, Driesen A, Van Vlierberghe P, Vanden Berghe W Int J Mol Sci. 2021; 22(23).

PMID: 34884535 PMC: 8657914. DOI: 10.3390/ijms222312731.

References

Mellinghoff I, Wang M, Vivanco I, Haas-Kogan D, Zhu S, Dia E . Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005; 353(19):2012-24. DOI: 10.1056/NEJMoa051918. View

Shi Y, Yan H, Frost P, Gera J, Lichtenstein A . Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther. 2005; 4(10):1533-40. DOI: 10.1158/1535-7163.MCT-05-0068. View

Fan Q, Knight Z, Goldenberg D, Yu W, Mostov K, Stokoe D . A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell. 2006; 9(5):341-9. PMC: 2925230. DOI: 10.1016/j.ccr.2006.03.029. View

Vogt P, Bader A, Kang S . PI 3-kinases: hidden potentials revealed. Cell Cycle. 2006; 5(9):946-9. DOI: 10.4161/cc.5.9.2725. View

Knight Z, Gonzalez B, Feldman M, Zunder E, Goldenberg D, Williams O . A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006; 125(4):733-47. PMC: 2946820. DOI: 10.1016/j.cell.2006.03.035. View

Shaw R, Cantley L . Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006; 441(7092):424-30. DOI: 10.1038/nature04869. View

Workman P, Clarke P, Guillard S, Raynaud F . Drugging the PI3 kinome. Nat Biotechnol. 2006; 24(7):794-6. DOI: 10.1038/nbt0706-794. View

Engelman J, Luo J, Cantley L . The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006; 7(8):606-19. DOI: 10.1038/nrg1879. View

Wang M, Lu K, Zhu S, Dia E, Vivanco I, Shackleford G . Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res. 2006; 66(16):7864-9. DOI: 10.1158/0008-5472.CAN-04-4392. View

10.

Sabatini D . mTOR and cancer: insights into a complex relationship. Nat Rev Cancer. 2006; 6(9):729-34. DOI: 10.1038/nrc1974. View

11.

Hayakawa M, Kaizawa H, Moritomo H, Koizumi T, Ohishi T, Okada M . Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem. 2006; 14(20):6847-58. DOI: 10.1016/j.bmc.2006.06.046. View

12.

Corradetti M, Guan K . Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?. Oncogene. 2006; 25(48):6347-60. DOI: 10.1038/sj.onc.1209885. View

13.

Hayakawa M, Kaizawa H, Kawaguchi K, Ishikawa N, Koizumi T, Ohishi T . Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem. 2006; 15(1):403-12. DOI: 10.1016/j.bmc.2006.09.047. View

14.

Zhao J, Roberts T . PI3 kinases in cancer: from oncogene artifact to leading cancer target. Sci STKE. 2006; 2006(365):pe52. DOI: 10.1126/stke.3652006pe52. View

15.

Nicholas M, Lukas R, Jafri N, Faoro L, Salgia R . Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res. 2006; 12(24):7261-70. DOI: 10.1158/1078-0432.CCR-06-0874. View

16.

Fan Q, Zhang C, Shokat K, Weiss W . Chemical genetic blockade of transformation reveals dependence on aberrant oncogenic signaling. Curr Biol. 2002; 12(16):1386-94. DOI: 10.1016/s0960-9822(02)01070-9. View

17.

Sadhu C, Dick K, Tino W, Staunton D . Selective role of PI3K delta in neutrophil inflammatory responses. Biochem Biophys Res Commun. 2003; 308(4):764-9. DOI: 10.1016/s0006-291x(03)01480-3. View

18.

Luo J, Manning B, Cantley L . Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 2003; 4(4):257-62. DOI: 10.1016/s1535-6108(03)00248-4. View

19.

Fan Q, Specht K, Zhang C, Goldenberg D, Shokat K, Weiss W . Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach. Cancer Res. 2003; 63(24):8930-8. View

20.

Knight Z, Chiang G, Alaimo P, Kenski D, Ho C, Coan K . Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg Med Chem. 2004; 12(17):4749-59. DOI: 10.1016/j.bmc.2004.06.022. View